Neuromodulation catheters having jacketed neuromodulation elements and related devices, systems, and methods

Information

  • Patent Grant
  • 11154353
  • Patent Number
    11,154,353
  • Date Filed
    Friday, December 21, 2018
    5 years ago
  • Date Issued
    Tuesday, October 26, 2021
    2 years ago
Abstract
A neuromodulation catheter in accordance with a particular embodiment includes an elongate shaft and a neuromodulation element operably connected to the shaft. The shaft includes a proximal hypotube segment at its proximal end portion and a jacket disposed around at least a portion of an outer surface of the hypotube segment. The jacket may be made at least partially of a polymer blend including polyether block amide and polysiloxane. The neuromodulation element includes a distal hypotube segment and a tubular jacket disposed around at least a portion of an outer surface of the distal hypotube segment. The jacket has reduced-diameter segments spaced apart along its longitudinal axis. The neuromodulation element further includes band electrodes respectively seated in the reduced-diameter segments and respectively forming closed loops extending circumferentially around the jacket.
Description
TECHNICAL FIELD

The present technology is related to catheters. In particular, at least some embodiments are related to neuromodulation catheters including neuromodulation elements configured to deliver energy to nerves at or near a treatment location within a body lumen.


BACKGROUND

The sympathetic nervous system (SNS) is a primarily involuntary bodily control system typically associated with stress responses. Fibers of the SNS extend through tissue in almost every organ system of the human body and can affect characteristics such as pupil diameter, gut motility, and urinary output. Such regulation can have adaptive utility in maintaining homeostasis or in preparing the body for rapid response to environmental factors. Chronic activation of the SNS, however, is a common maladaptive response that can drive the progression of many disease states. Excessive activation of the renal SNS, in particular, has been identified experimentally and in humans as a likely contributor to the complex pathophysiologies of hypertension, states of volume overload (e.g., heart failure), and progressive renal disease.


Sympathetic nerves of the kidneys terminate in the renal blood vessels, the juxtaglomerular apparatus, and the renal tubules, among other structures. Stimulation of the renal sympathetic nerves can cause, for example, increased renin release, increased sodium reabsorption, and reduced renal blood flow. These and other neural-regulated components of renal function are considerably stimulated in disease states characterized by heightened sympathetic tone. For example, reduced renal blood flow and glomerular filtration rate as a result of renal sympathetic efferent stimulation is likely a cornerstone of the loss of renal function in cardio-renal syndrome (i.e., renal dysfunction as a progressive complication of chronic heart failure). Pharmacologic strategies to thwart the consequences of renal sympathetic stimulation include centrally-acting sympatholytic drugs, beta blockers (e.g., to reduce renin release), angiotensin-converting enzyme inhibitors and receptor blockers (e.g., to block the action of angiotensin II and aldosterone activation consequent to renin release), and diuretics (e.g., to counter renal sympathetic mediated sodium and water retention). These pharmacologic strategies, however, have significant limitations including limited efficacy, compliance issues, side effects, and others.





BRIEF DESCRIPTION OF THE DRAWINGS

Many aspects of the present technology can be better understood with reference to the following drawings. The components in the drawings are not necessarily to scale. Instead, emphasis is placed on illustrating clearly the principles of the present technology. For ease of reference, throughout this disclosure identical reference numbers may be used to identify identical or at least generally similar or analogous components or features.



FIG. 1 is a partially schematic perspective view illustrating a therapeutic system configured in accordance with an embodiment of the present technology. The system is shown in FIG. 1 including a neuromodulation catheter having a shaft.



FIG. 2 is an exploded profile view of the catheter shown in FIG. 1.



FIGS. 3, 4 and 6 are enlarged exploded profile views of portions of the catheter shown in FIG. 1 taken at respective locations designated in FIG. 2.



FIG. 5 is a further enlarged cross-sectional view of an intermediate tube of the shaft shown in FIG. 1 taken along a line 5-5 designated in FIG. 4.



FIG. 7 is a profile view of a proximal hypotube segment and a proximal jacket of the shaft shown in FIG. 1.



FIG. 8 is a cross-sectional profile view of the proximal hypotube segment and the proximal jacket shown in FIG. 7 taken along a line 8-8 designated in FIG. 7.



FIG. 9 is an enlarged profile view of a portion of the proximal hypotube segment and the proximal jacket shown in FIG. 7 taken at a location designated in FIG. 7.



FIG. 10 is a perspective view of a distal jacket of a neuromodulation element of a neuromodulation catheter configured in accordance with an embodiment of the present technology. The distal jacket is shown in FIG. 10 including reduced-diameter segments.



FIG. 11 is a profile view of the distal jacket shown in FIG. 10 and band electrodes respectively seated in the reduced-diameter segments.



FIG. 12 is a profile view of the distal jacket shown in FIG. 10.



FIG. 13 is an enlarged profile view of a portion of the distal jacket shown in FIG. 9 taken at a location designated in FIG. 12.



FIG. 14 is a cross-sectional profile view of the distal jacket shown in FIG. 10 taken along a line 14-14 designated in FIG. 12.



FIGS. 15-17 are enlarged cross-sectional profile views of a portion of the distal jacket shown in FIG. 10 at a location designated in FIG. 14. The portion of the distal jacket shown in FIGS. 15-17 includes one of the reduced-diameter segments shown in FIG. 10. In FIG. 15, the portion of the distal jacket is shown without a band electrode. In FIG. 16, the portion of the distal jacket is shown resiliently deformed inwardly as a band electrode is moved toward the reduced-diameter segment. In FIG. 17, the portion of the distal jacket is shown with the band electrode seated in the reduced-diameter segment.



FIG. 18 is an enlarged cross-sectional profile view of a sidewall of one of the reduced-diameter segments shown in FIG. 10 at a location designated in FIG. 15.



FIGS. 19 and 20 are enlarged cross-sectional profile views of sidewalls of reduced-diameter segments having configurations different than the configuration of the sidewall shown in FIG. 18.



FIG. 21 is a flow chart illustrating a method for making a neuromodulation element including the distal jacket shown in FIG. 10 and the band electrodes shown in FIG. 11 in accordance with an embodiment of the present technology.





DETAILED DESCRIPTION

Specific details of systems, devices, and methods in accordance with several embodiments of the present technology are disclosed herein with reference to FIGS. 1-21. Although the systems, devices, and methods may be disclosed herein primarily or entirely with respect to intravascular renal neuromodulation, other applications in addition to those disclosed herein are within the scope of the present technology. For example, systems, devices, and methods in accordance with at least some embodiments of the present technology may be useful for neuromodulation within a body lumen other than a vessel, for extravascular neuromodulation, for non-renal neuromodulation, and/or for use in therapies other than neuromodulation. Furthermore, it should understood, in general, that other systems, devices, and methods in addition to those disclosed herein are within the scope of the present technology. For example, systems, devices, and methods in accordance with embodiments of the present technology can have different and/or additional configurations, components, and procedures than those disclosed herein. Moreover, a person of ordinary skill in the art will understand that systems, devices, and methods in accordance with embodiments of the present technology can be without one or more of the configurations, components, and/or procedures disclosed herein without deviating from the present technology.


As used herein, the terms “distal” and “proximal” define a position or direction with respect to a clinician or a clinician's control device (e.g., a handle of a catheter). The terms, “distal” and “distally” refer to a position distant from or in a direction away from a clinician or a clinician's control device. The terms “proximal” and “proximally” refer to a position near or in a direction toward a clinician or a clinician's control device. The headings provided herein are for convenience only and should not be construed as limiting the subject matter disclosed.


Selected Examples of Neuromodulation Catheters and Related Systems and Devices



FIG. 1 is a partially schematic perspective view illustrating a therapeutic system 100 configured in accordance with an embodiment of the present technology. The system 100 can include a neuromodulation catheter 102, a console 104, and a cable 106 extending between the catheter 102 and the console 104. The catheter 102 can include an elongate shaft 108 having a proximal end portion 108a, a distal end portion 108b, and an intermediate portion 108c therebetween. The catheter 102 can further include a handle 110 operably connected to the shaft 108 via the proximal end portion 108a of the shaft 108 and a neuromodulation element 112 (shown schematically in FIG. 1) operably connected to the shaft 108 via the distal end portion 108b of the shaft 108. The shaft 108 can be configured to locate the neuromodulation element 112 at a treatment location within or otherwise proximate to a body lumen (e.g., a blood vessel, a duct, an airway, or another naturally occurring lumen within the human body). In some embodiments, the shaft 108 can be configured to locate the neuromodulation element 112 at an intraluminal (e.g., intravascular) location. The neuromodulation element 112 can be configured to provide or support a neuromodulation treatment at the treatment location. The shaft 108 and the neuromodulation element 112 can be 2, 3, 4, 5, 6, or 7 French or other suitable sizes.


Intraluminal delivery of the catheter 102 can include percutaneously inserting a guide wire (not shown) into a body lumen of a patient and moving the shaft 108 and the neuromodulation element 112 along the guide wire until the neuromodulation element 112 reaches a suitable treatment location. Alternatively, the catheter 102 can be a steerable or non-steerable device configured for use without a guide wire. As another alternative, the neuromodulation catheter 102 can be configured for use with a guide catheter or sheath (not shown). In the illustrated embodiment, the console 104 is configured to control, monitor, supply, and/or otherwise support operation of the catheter 102. In other embodiments, the catheter 102 can be self-contained or otherwise configured for operation independent of the console 104. When present, the console 104 can be configured to generate a selected form and/or magnitude of energy for delivery to tissue at a treatment location via the neuromodulation element 112. For example, the console 104 can be configured to generate radio frequency (RF) energy (e.g., monopolar and/or bipolar RF energy) and/or another suitable type of energy for delivery to tissue at a treatment location via electrodes (not shown) of the neuromodulation element 112. Along the cable 106 or at another suitable location within the system 100, the system 100 can include a control device 114 configured to initiate, terminate, and/or adjust operation of one or more components of the catheter 102 directly and/or via the console 104. The console 104 can be configured to execute an automated control algorithm 116 and/or to receive control instructions from an operator. Similarly, the console 104 can be configured to provide feedback to an operator before, during, and/or after a treatment procedure via an evaluation/feedback algorithm 118.



FIG. 2 is an exploded profile view of the catheter 102. FIGS. 3, 4 and 6 are enlarged exploded profile views of portions of the catheter 102 taken at respective locations designated in FIG. 2. With reference to FIGS. 2-4 and 6 together, the handle 110 can include mating shell segments 120 (individually identified as shell segments 120a, 120b) and a connector 122 (e.g., a luer connector) operably positioned between the mating shell segments 120. The handle 110 can further include a distally tapered strain-relief element 124 operably connected to distal ends of the shell segments 120. Slidably positioned over the shaft 108, the catheter 102 can include a loading tool 126 configured to facilitate loading the catheter 102 onto a guide wire (not shown). When assembled, the shaft 108 can extend through coaxial lumens (also not shown) of the strain-relief element 124 and the loading tool 126, respectively, and between the shell segments 120 to the connector 122.


The shaft 108 can include an assembly of parallel tubular segments. At its proximal end portion 108a and extending distally though a majority of its intermediate portion 108c, the shaft 108 can include a proximal hypotube segment 128, a proximal jacket 130, a first electrically insulative tube 132, and a guide-wire tube 134. The first electrically insulative tube 132 and the guide-wire tube 134 can be disposed side-by-side within the proximal hypotube segment 128. The first electrically insulative tube 132 can be configured to carry electrical leads (not shown) and to electrically insulate the electrical leads from the proximal hypotube segment 128. The guide-wire tube 134 can be configured to carry a guide wire (not shown). The proximal jacket 130 can be disposed around at least a portion of an outer surface of the proximal hypotube segment 128. The proximal hypotube segment 128 can include a proximal stem 136 at its proximal end and a distal skive 138 at its distal end. The proximal jacket 130 and the proximal hypotube segment 128 are discussed in greater detail below with reference to FIGS. 7-9.


With reference again to FIGS. 2-4 and 6, the first electrically insulative tube 132 and the guide-wire tube 134 can extend distally beyond the distal skive 138. The shaft 108 can include an intermediate tube 140 beginning proximally at a region of the shaft 108 at which the first electrically insulative tube 132 and the guide-wire tube 134 distally emerge from the proximal hypotube segment 128. The intermediate tube 140 can be more flexible than the proximal hypotube segment 128. At the region of the shaft 108 at which the first electrically insulative tube 132 and the guide-wire tube 134 distally emerge from the proximal hypotube segment 128, the intermediate tube 140 can be coaxially aligned with the proximal hypotube segment 128 so as to receive the first electrically insulative tube 132 and the guide-wire tube 134. From this region, the intermediate tube 140 can extend distally to the distal end portion 108b of the shaft 108. The first electrically insulative tube 132 can distally terminate within the intermediate tube 140. In contrast, the guide-wire tube 134 can extend through the entire length of the intermediate tube 140. At a distal end of the intermediate tube 140, the shaft 108 can be operably connected to the neuromodulation element 112.



FIG. 5 is a further enlarged cross-sectional view of the intermediate tube 140 taken along a line 5-5 designated in FIG. 4. Arranged from innermost to outermost, the intermediate tube 140 can include an inner polymer layer 140a, a metal braid 140b, a first outer polymer layer 140c, and a second outer polymer layer 140d. In a particular embodiment, the inner polymer layer 140a is made of polyimide (e.g., about 0.006 inch thick); the metal braid 140b is made of stainless steel; the first outer polymer layer 140c is made of coated polyimide (e.g., three coats); and the second outer polymer layer 140d is made of polyether block amide (e.g., PEBAX®) (e.g., about 0.00125 inch thick). Other suitable compositions and arrangements are also possible. In some embodiments, at least a portion of the intermediate tube 140 is film-cast. For example, disposing the first outer polymer layer 140c onto the metal braid 140b as a series of thin films can allow the thickness of the first outer polymer layer 140c to be precisely controlled. Accordingly, the first outer polymer layer 140c can be just thick enough to prevent the ends of the metal braid 140b from becoming exposed or otherwise damaged when thermally bonding the intermediate tube 140 to the proximal and distal hypotube segments 128, 142, respectively, but not so thick as to cause the intermediate tube 140 to become excessively stiff. This can reduce or eliminate the need to locally reinforce the ends of the intermediate tube 140 or to splice coupling components onto the ends of the intermediate tube 140 to facilitate bonding the intermediate tube 140 to the proximal and distal hypotube segments 128, 142.


The neuromodulation element 112 can include a distal hypotube segment 142 coupled to the distal end of the intermediate tube 140. The neuromodulation element 112 can also include a distal jacket 144 disposed around at least a portion of an outer surface of the distal hypotube segment 142. As shown, the neuromodulation element 112 can further include band electrodes 146 disposed outside the distal jacket 144 at spaced-apart positions along a longitudinal axis of the distal jacket 144. At a distal end of the distal hypotube segment 142, the neuromodulation element 112 can include a distally tapering atraumatic tip 148. The guide-wire tube 134 can extend through the distal hypotube segment 142 to a distal opening 150 of the tip 148. The electrical leads can respectively extend through the distal hypotube segment 142 to the band electrodes 146.


In FIGS. 2 and 6, the neuromodulation element 112 is shown in a radially expanded deployed state. The neuromodulation element 112 can be movable from a low-profile delivery state to the radially expanded deployed state. When the neuromodulation element 112 is in the radially expanded deployed state, the distal hypotube segment 142 can have a shape that is more helical (spiral) than its shape when the neuromodulation element 112 is in the low-profile delivery state. In at least some cases, the distal hypotube segment 142 has the more helical shape when at rest and is configured to be forced into the less helical shape by an external sheath (not shown). The distal hypotube segment 142 can be made at least partially of nitinol, stainless steel, or another suitable material well suited for resiliently moving between the more helical and less helical shapes. In at least some cases, the material of the distal hypotube segment 142 is electrically conductive. Accordingly, the neuromodulation element 112 can include a second electrically insulative tube 152 disposed around an outer surface of the distal hypotube segment 142 so as to electrically separate the band electrodes 146 from the distal hypotube segment 142. In some embodiments, the first and second electrically insulative tubes 132, 152 are made at least partially (e.g., predominantly or entirely) of polyimide and polyether block amide, respectively. In other embodiments, the first and second electrically insulative tubes 132, 152 can be made of other suitable materials.



FIG. 7 is a profile view of the proximal hypotube segment 128 and the proximal jacket 130. FIG. 8 is a cross-sectional profile view of the proximal hypotube segment 128 and the proximal jacket 130 taken along a line 8-8 designated in FIG. 7. FIG. 9 is an enlarged profile view of a portion of the proximal hypotube segment 128 and the proximal jacket 130 taken at a location designated in FIG. 7. As shown in FIGS. 7 and 8, the proximal jacket 130 can be absent from the outer surface of the proximal hypotube segment 128 at the proximal stem 136. This can be useful, for example, to facilitate connecting the proximal hypotube segment 128 to the connector 122. In contrast, the proximal jacket 130 can be disposed on at least a portion of the outer surface of the proximal hypotube segment 128 at the distal skive 138. In some embodiments, the proximal hypotube segment 128 is made at least partially (e.g., predominantly or entirely) of nitinol. In these and other embodiments, the proximal jacket 130 can be made at least partially (e.g., predominantly or entirely) of a polymer blend including polyether block amide and polysiloxane. For example, the polymer blend can include greater than 15% polysiloxane. In a particular embodiment, the polymer blend includes about 20% by weight polyether block amide and about 80% by weight polyether block amide. This material may allow the proximal jacket 130 to have sufficient lubricity for use without an outer coating, among other potential advantages. In still other embodiments, the proximal hypotube segment 128 and the proximal jacket 130 can be made of other suitable materials.



FIG. 10 is a perspective view of a distal jacket 200 of a neuromodulation element of a neuromodulation catheter configured in accordance with an embodiment of the present technology. The distal jacket 200, for example, can be used in the neuromodulation element 112 (FIGS. 1, 2 and 6) in place of the distal jacket 144 (FIGS. 2 and 6). Accordingly, the distal jacket 200 may be described below in conjunction with components of the catheter 102 (FIGS. 1 and 2). The distal jacket 200 can include reduced-diameter segments 202 (individually identified as reduced-diameter segments 202a-202d) extending through its outer surface. FIG. 11 is a profile view of the distal jacket 200 and band electrodes 204 (individually identified as band electrodes 204a-204d) respectively seated in the reduced-diameter segments 202. FIG. 12 is a profile view of the distal jacket 200 without the band electrodes 204. FIG. 13 is an enlarged profile view of a portion of the distal jacket 200 taken at a location designated in FIG. 12. FIG. 14 is a cross-sectional profile view of the distal jacket 200 taken along a line 14-14 designated in FIG. 12.


With reference to FIGS. 10-14 together, the distal jacket 200 can be tubular and configured to be disposed around at least a portion of an outer surface of the distal hypotube segment 142 (FIGS. 2 and 6). The reduced-diameter segments 202 can be insets, pockets, grooves, or other suitable features configured to respectively seat the band electrodes 204. In the illustrated embodiment, the distal jacket 200 includes exactly four reduced-diameter segments 202 spaced apart along its longitudinal axis. Alternatively, the distal jacket 200 can include exactly one, two, three, five, six or a greater number of reduced-diameter segments 202. The reduced-diameter segments 202 may be spaced apart at equal distances or at different distances. The distal jacket 200 can include openings 206 respectively positioned at the reduced-diameter segments 202. A neuromodulation catheter including the distal jacket 200 can include electrical leads (not shown) extending from respective reduced-diameter segments 202, through respective openings 206, through a lumen of the distal hypotube segment 142 (FIGS. 2 and 6), through the intermediate tube 140, and through the proximal hypotube segment 128 to the handle 110. In this way, the electrical leads can respectfully connect the band electrodes 204 to proximal components of a neuromodulation catheter including the distal jacket 200.



FIGS. 15-17 are enlarged cross-sectional profile views of a portion of the distal jacket 200 at a location designated in FIG. 14. At this location, the distal jacket 200 can include the reduced-diameter segment 202a. In FIG. 15, the portion of the distal jacket 200 is shown without the band electrode 204a corresponding to the reduced-diameter segment 202a. In FIG. 16, the portion of the distal jacket 200 is shown resiliently deformed inwardly as the band electrode 204a is moved toward the reduced-diameter segment 202a. In FIG. 17, the portion of the distal jacket 200 is shown with the band electrode 204a seated in the reduced-diameter segment 202a. With reference to FIGS. 10-17 together, the band electrodes 204 can respectively form closed loops extending circumferentially around the distal jacket 200. In at least some cases, a minimum inner diameter of the band electrodes 204 is smaller than a maximum outer diameter of distal jacket 200 between the reduced-diameter segments 202. To facilitate assembly, the distal jacket 200 between the reduced-diameter segments 202 can be resilient in response to peristaltic deflection of a magnitude corresponding to a difference between the maximum outer diameter of the distal jacket 200 between the reduced-diameter segments 202 and the minimum inner diameter of the band electrodes 204. Suitable materials for the distal jacket 200 include polymer blends including polyurethane and polysiloxane, among others.


A maximum outer diameter of the band electrodes 204 and the maximum outer diameter of the distal jacket 200 between the reduced-diameter segments 202 can be at least generally equal (e.g., within 5%, 3%, or 2% of one another). Thus, once the band electrodes 204 are respectively seated in the reduced-diameter segments 202, outer surfaces of the band electrodes 204 and the distal jacket 200 between the reduced-diameter segments 202 can be at least generally flush. This can be useful, for example, to reduce or eliminate potentially problematic ridges (e.g., circumferential steps) at distal and proximal ends of the individual band electrodes 204. This, in turn, can reduce or eliminate the need for fillets (e.g., adhesive fillets, such as glue fillets) at the distal and proximal ends of the individual band electrodes 204. In at least some embodiments, the distal jacket 200 and the band electrodes 204 can be bonded to one another without any exposed adhesive. For example, an adhesive (not shown) can be disposed between the band electrodes 204 and the distal jacket 200 at the reduced-diameter segments 202.



FIG. 18 is an enlarged cross-sectional profile view of a sidewall of the reduced-diameter segment 202a at a location designated in FIG. 15. As shown in FIG. 18, the reduced-diameter segment 202a can include a floor 206, a sidewall 208, and a corner 210 therebetween. The distal jacket 200 can further include a rim 212 bordering the reduced-diameter segment 202a. In the illustrated embodiment, the sidewall 208 is vertical and perpendicular to the floor 206 and the rim 212. In particular, the sidewall 208 meets the floor 206 and the rim 212 at a 90° angle and a 270° angle, respectively. This configuration of the sidewall 208 can facilitate secure seating of a band electrode (not shown in FIG. 18) in the reduced-diameter segment 202a without a gap being formed between the band electrode and an upper portion of the sidewall 208. Such a gap can be problematic, for example, because it can present an edge that may interfere with smooth movement of the distal jacket 200 through a patient's vasculature. Disadvantageously, tensile loading on the distal jacket 200 may tend to concentrate at the corner 210. This can adversely affect the durability of the distal jacket 200.


Sidewall configurations different than the configuration shown in FIG. 18 may be advantageous in at least some cases. FIGS. 19 and 20 illustrate two examples of such alternative configurations. FIG. 19, in particular, is an enlarged cross-sectional profile view of a portion of a distal jacket 300 including a reduced-diameter segment 302 having a floor 304, a sidewall 306, and a rounded junction 308 therebetween. The distal jacket 300 can further include a rim 310 bordering the reduced-diameter segment 302. In the illustrated embodiment, the sidewall 306 is slanted relative to the floor 304 and the rim 310. The reduced-diameter segment 302 can have a depth (D) between the floor 304 and the rim 310. The rounded junction 308 can have a radius (R) within a range from 25% to 50% of the depth. In at least some embodiments, the radius is within a range from 0.5 mil to 3 mils (e.g., a range from 1 mil to 2 mils). The shape of the rounded junction 308 can promote diffusion of tensile loading on the distal jacket 300, thereby enhancing the durability of the distal jacket 300. Furthermore, the sidewall 306 and the rounded junction 308 can be entirely on one side of a plane along which a portion of the floor 304 directly adjacent to the rounded junction 308 lies. Because the sidewall 306 and the rounded junction 308 do not extend through this plane, the material thickness of the distal jacket 300 at the rounded junction 308 can be no less than the material thickness of the distal jacket 300 elsewhere along the reduced-diameter segment 302. Correspondingly, the tensile strength of the distal jacket 300 at the rounded junction 308 can be no less than the material thickness of the distal jacket 300 elsewhere along the reduced-diameter segment 302.



FIG. 20 is an enlarged cross-sectional profile view of a portion of a distal jacket 400 including a reduced-diameter segment 402 having a floor 404, a sidewall 406, and a rounded junction 408 therebetween. The distal jacket 400 can further include a rim 410 bordering the reduced-diameter segment 402. In the illustrated embodiment, the sidewall 406 is more vertical relative to the floor 404 and the rim 410 than the sidewall 306 of the reduced-diameter segment 302 shown in FIG. 19. In at least some embodiments, the sidewall 406 from the rounded junction 408 to the rim 410 has an average angle (A) greater than 240° (e.g., greater than 260°) relative to the rim 410. As discussed above with reference to FIG. 18, vertical or near-vertical orientation of the sidewall 406 can facilitate secure seating of a band electrode (not shown in FIG. 20) in the reduced-diameter segment 402 without a gap or with only a minor gap being formed between the band electrode and an upper portion of the sidewall 406.


Selected Examples of Manufacturing Methods for Neuromodulation Elements



FIG. 21 is a flow chart illustrating a method 500 for making a neuromodulation element including the distal jacket 200 and the band electrodes 204 in accordance with an embodiment of the present technology. With reference to FIGS. 10-21 together, the method 500 can begin with forming the distal jacket 200. This can include forming a tubular blank (block 502) (e.g., by extrusion) and then using a subtractive process (e.g., by laser ablation) to remove portions of the blank and thereby form the reduced-diameter segments 202 (block 504). The same or a different subtractive process can be used to form the openings 206 (block 506). Alternatively, the distal jacket 200 can be formed by injection molding or another suitable technique that allows the reduced-diameter segments 202 and/or the openings 206 to be formed without the need for a subtractive process. When a subtractive process is used to form the reduced-diameter segments 202, the subtractive process can be precisely controlled so as to leave an innermost portion of a wall of the distal jacket 200 intact at the reduced-diameter segments 202. Laser ablation is one example of a suitable subtractive process for forming the reduced-diameter segments 202. Laser ablation can include loading the blank onto a mandrel and then rotating the blank and the mandrel relative to an ablative laser (or rotating the ablative laser relative to the black and the mandrel) under computerized control. The mandrel can conductively cool the innermost portion of the wall of the distal jacket 200 so as to prevent this portion of the wall from reaching ablative temperatures at the reduced-diameter segments 202. Furthermore, laser ablation and other subtractive processes can be carefully controlled to avoid forming a notch or other indentation in the distal jacket 200 below the floor 206 at the corner 210. When present, such an indentation may unduly decrease the tensile strength of the distal jacket 200. Other techniques for forming the reduced-diameter segments 202 are also possible.


The method 500 can further include jacketing the distal hypotube segment 142 (block 508), such as by positioning the distal jacket 200 and the distal hypotube segment 142 relative to one another so that the distal jacket 200 is disposed around at least a portion of an outer surface of the distal hypotube segment 142. In at least some embodiments, the form and/or other aspects of the distal jacket 200 may allow the distal jacket 200 to be disposed around at least a portion of the outer surface of the distal hypotube segment 142 without swaging the distal jacket 200. When the distal hypotube segment 142 is positioned within the distal jacket 200, the method 500 can include respectively stringing electrical leads (block 510) from the reduced-diameter segments 202 through a lumen of the distal hypotube segment 142. Next, the method 500 can include dispensing an adhesive (block 512) onto the distal jacket 200 at the reduced-diameter segment 202d. Then, the method 500 can include positioning the band electrode 204d (block 514) at the reduced-diameter segment 202d. As discussed above with reference to FIGS. 15-17, positioning the band electrode 204d can include resiliently deforming the distal jacket 200 inwardly while passing (e.g., advancing or threading) the distal jacket 200 through a channel of the band electrode 204d so as to move the band electrode 204d toward a longitudinal position at which the band electrode 204d is aligned with the reduced-diameter segment 202d. The same process can be used to install the band electrodes 204c, the band electrode 204b, and finally the band electrode 204a.


Renal Neuromodulation


Catheters configured in accordance with at least some embodiments of the present technology can be well suited (e.g., with respect to sizing, flexibility, operational characteristics, and/or other attributes) for performing renal neuromodulation in human patients. Renal neuromodulation is the partial or complete incapacitation or other effective disruption of nerves of the kidneys (e.g., nerves terminating in the kidneys or in structures closely associated with the kidneys). In particular, renal neuromodulation can include inhibiting, reducing, and/or blocking neural communication along neural fibers (e.g., efferent and/or afferent neural fibers) of the kidneys. Such incapacitation can be long-term (e.g., permanent or for periods of months, years, or decades) or short-term (e.g., for periods of minutes, hours, days, or weeks). Renal neuromodulation is expected to contribute to the systemic reduction of sympathetic tone or drive and/or to benefit at least some specific organs and/or other bodily structures innervated by sympathetic nerves. Accordingly, renal neuromodulation is expected to be useful in treating clinical conditions associated with systemic sympathetic overactivity or hyperactivity, particularly conditions associated with central sympathetic overstimulation. For example, renal neuromodulation is expected to efficaciously treat hypertension, heart failure, acute myocardial infarction, metabolic syndrome, insulin resistance, diabetes, left ventricular hypertrophy, chronic and end stage renal disease, inappropriate fluid retention in heart failure, cardio-renal syndrome, polycystic kidney disease, polycystic ovary syndrome, osteoporosis, erectile dysfunction, and sudden death, among other conditions.


Renal neuromodulation can be electrically-induced, thermally-induced, or induced in another suitable manner or combination of manners at one or more suitable treatment locations during a treatment procedure. The treatment location can be within or otherwise proximate to a renal lumen (e.g., a renal artery, a ureter, a renal pelvis, a major renal calyx, a minor renal calyx, or another suitable structure), and the treated tissue can include tissue at least proximate to a wall of the renal lumen. For example, with regard to a renal artery, a treatment procedure can include modulating nerves in the renal plexus, which lay intimately within or adjacent to the adventitia of the renal artery. Various suitable modifications can be made to the catheters described above to accommodate different treatment modalities. For example, the band electrodes 204 (FIG. 11) can be replaced with transducers to facilitate transducer-based treatment modalities.


Renal neuromodulation can include an electrode-based or treatment modality alone or in combination with another treatment modality. Electrode-based or transducer-based treatment can include delivering electricity and/or another form of energy to tissue at or near a treatment location to stimulate and/or heat the tissue in a manner that modulates neural function. For example, sufficiently stimulating and/or heating at least a portion of a sympathetic renal nerve can slow or potentially block conduction of neural signals to produce a prolonged or permanent reduction in renal sympathetic activity. A variety of suitable types of energy can be used to stimulate and/or heat tissue at or near a treatment location. For example, neuromodulation in accordance with embodiments of the present technology can include delivering RF energy, pulsed electrical energy, microwave energy, optical energy, focused ultrasound energy (e.g., high-intensity focused ultrasound energy), and/or another suitable type of energy. An electrode or transducer used to deliver this energy can be used alone or with other electrodes or transducers in a multi-electrode or multi-transducer array.


Neuromodulation using focused ultrasound energy (e.g., high-intensity focused ultrasound energy) can be beneficial relative to neuromodulation using other treatment modalities. Focused ultrasound is an example of a transducer-based treatment modality that can be delivered from outside the body. Focused ultrasound treatment can be performed in close association with imaging (e.g., magnetic resonance, computed tomography, fluoroscopy, ultrasound (e.g., intravascular or intraluminal), optical coherence tomography, or another suitable imaging modality). For example, imaging can be used to identify an anatomical position of a treatment location (e.g., as a set of coordinates relative to a reference point). The coordinates can then entered into a focused ultrasound device configured to change the power, angle, phase, or other suitable parameters to generate an ultrasound focal zone at the location corresponding to the coordinates. The focal zone can be small enough to localize therapeutically-effective heating at the treatment location while partially or fully avoiding potentially harmful disruption of nearby structures. To generate the focal zone, the ultrasound device can be configured to pass ultrasound energy through a lens, and/or the ultrasound energy can be generated by a curved transducer or by multiple transducers in a phased array, which can be curved or straight.


Heating effects of electrode-based or transducer-based treatment can include ablation and/or non-ablative alteration or damage (e.g., via sustained heating and/or resistive heating). For example, a treatment procedure can include raising the temperature of target neural fibers to a target temperature above a first threshold to achieve non-ablative alteration, or above a second, higher threshold to achieve ablation. The target temperature can be higher than about body temperature (e.g., about 37° C.) but less than about 45° C. for non-ablative alteration, and the target temperature can be higher than about 45° C. for ablation. Heating tissue to a temperature between about body temperature and about 45° C. can induce non-ablative alteration, for example, via moderate heating of target neural fibers or of luminal structures that perfuse the target neural fibers. In cases where luminal structures are affected, the target neural fibers can be denied perfusion resulting in necrosis of the neural tissue. Heating tissue to a target temperature higher than about 45° C. (e.g., higher than about 60° C.) can induce ablation, for example, via substantial heating of target neural fibers or of luminal structures that perfuse the target fibers. In some patients, it can be desirable to heat tissue to temperatures that are sufficient to ablate the target neural fibers or the luminal structures, but that are less than about 90° C. (e.g., less than about 85° C., less than about 80° C., or less than about 75° C.).


Conclusion


This disclosure is not intended to be exhaustive or to limit the present technology to the precise forms disclosed herein. Although specific embodiments are disclosed herein for illustrative purposes, various equivalent modifications are possible without deviating from the present technology, as those of ordinary skill in the relevant art will recognize. In some cases, well-known structures and functions have not been shown and/or described in detail to avoid unnecessarily obscuring the description of the embodiments of the present technology. Although steps of methods may be presented herein in a particular order, in alternative embodiments the steps may have another suitable order. Similarly, certain aspects of the present technology disclosed in the context of particular embodiments can be combined or eliminated in other embodiments. Furthermore, while advantages associated with certain embodiments may have been disclosed in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments need necessarily exhibit such advantages or other advantages disclosed herein to fall within the scope of the present technology. Accordingly, this disclosure and associated technology can encompass other embodiments not expressly shown and/or described herein.


The methods disclosed herein include and encompass, in addition to methods of practicing the present technology (e.g., methods of making and using the disclosed devices and systems), methods of instructing others to practice the present technology. For example, a method in accordance with a particular embodiment includes forming a tubular jacket, resiliently deforming the jacket inwardly while passing the jacket through a channel of a band electrode, and positioning the jacket and a hypotube segment relative to one another so that the jacket is disposed around at least a portion of an outer surface of the hypotube segment. A method in accordance with another embodiment includes instructing such a method.


Throughout this disclosure, the singular terms “a,” “an,” and “the” include plural referents unless the context clearly indicates otherwise. Similarly, unless the word “or” is expressly limited to mean only a single item exclusive from the other items in reference to a list of two or more items, then the use of “or” in such a list is to be interpreted as including (a) any single item in the list, (b) all of the items in the list, or (c) any combination of the items in the list. Additionally, the terms “comprising” and the like are used throughout this disclosure to mean including at least the recited feature(s) such that any greater number of the same feature(s) and/or one or more additional types of features are not precluded. Directional terms, such as “upper,” “lower,” “front,” “back,” “vertical,” and “horizontal,” may be used herein to express and clarify the relationship between various elements. It should be understood that such terms do not denote absolute orientation. Reference herein to “one embodiment,” “an embodiment,” or similar formulations means that a particular feature, structure, operation, or characteristic described in connection with the embodiment can be included in at least one embodiment of the present technology. Thus, the appearances of such phrases or formulations herein are not necessarily all referring to the same embodiment. Furthermore, various particular features, structures, operations, or characteristics may be combined in any suitable manner in one or more embodiments of the present technology.

Claims
  • 1. A catheter comprising: an elongate shaft comprising a proximal segment; anda neuromodulation element connected to the shaft, the neuromodulation element being movable from a low-profile delivery state to a radially expanded deployed state, the neuromodulation element including: an outer perimeter;a distal segment configured to have a first shape when the neuromodulation element is in the delivery state and a second shape when the neuromodulation element is in the deployed state, the second shape being more helical than the first shape;a jacket disposed around at least a portion of an outer surface of the distal segment, an outer surface of the jacket comprising a plurality of reduced-diameter segments spaced apart along a longitudinal axis of the jacket, wherein each reduced-diameter segment of the plurality of reduced-diameter segments has a smaller outer diameter than an outer diameter of an adjoining portion of the outer surface of the jacket; anda plurality of electrodes, each electrode of the plurality of electrodes being seated in a respective reduced-diameter segment of the plurality of reduced diameter segments, and wherein the outer perimeter of the neuromodulation element comprises an outer surface of each electrode.
  • 2. The catheter of claim 1, wherein the plurality of electrodes comprise band electrodes.
  • 3. The catheter of claim 1, wherein each electrode forms a closed loop extending circumferentially around the jacket.
  • 4. The catheter of claim 1, wherein the jacket between the reduced-diameter segments is resilient in response to peristaltic deflection of a magnitude corresponding to a difference between a maximum outer diameter of the jacket between the reduced-diameter segments and a minimum inner diameter of the electrodes.
  • 5. The catheter of claim 1, further comprising adhesive disposed between the electrodes and the jacket at the reduced-diameter segments.
  • 6. The catheter of claim 1, wherein the reduced-diameter segments are fully circumferential.
  • 7. The catheter of claim 1, wherein the jacket defines openings at each of the reduced-diameter segments, and wherein the neuromodulation catheter further comprises a plurality of electrical leads, each lead being electrically connected to an electrode of the plurality of electrodes, the electrical leads each extending through a respective opening.
  • 8. The catheter of claim 1, wherein a maximum outer diameter of the electrodes and a maximum outer diameter of the jacket between the reduced-diameter segments are at least generally equal.
  • 9. The catheter of claim 1, wherein at least one of the reduced-diameter segments has a side wall, a floor, and a rounded junction therebetween.
  • 10. The catheter of claim 9, wherein a portion of the floor directly adjacent to the rounded junction lies along a plane, and wherein the wall and the rounded junction do not extend through the plane.
  • 11. The catheter of claim 9, wherein the jacket includes a rim bordering a respective reduced-diameter segment of the at least one reduced-diameter segment, the adjoining portion of the at least one reduced-diameter segment comprising the rim, and the respective reduced-diameter segment having a depth between the floor and the rim, and the rounded junction having a radius within a range from 35% to 50% of the depth.
  • 12. The catheter of claim 9, wherein the jacket includes a rim bordering a respective reduced-diameter segment of the at least one reduced-diameter segment, the adjoining portion of the at least one reduced-diameter segment comprising the rim, and the respective reduced-diameter segment having a depth between the floor and the rim, and the rounded junction having a radius within a range from 0.5 mil to 3 mils.
  • 13. The catheter of claim 9, wherein the jacket includes a rim bordering a respective reduced-diameter segment of the at least one reduced-diameter segment, the adjoining portion of the at least one reduced-diameter segment comprising the rim, and the sidewall from the junction to the rim having an average angle greater than 240° relative to the rim.
  • 14. The catheter of claim 1, wherein the jacket is made at least partially of a polymer.
  • 15. The catheter of claim 1, wherein the distal segment is made at least partially of nitinol or stainless steel.
  • 16. The catheter of claim 1, wherein the distal segment includes a proximal stem, and the jacket is not disposed around the outer surface of the distal segment at the proximal stem.
  • 17. The catheter of claim 1, wherein the neuromodulation element is connected to a distal end of the shaft, and wherein an inner diameter of each electrode is smaller than a maximum outer diameter of the jacket between the reduced-diameter segments.
  • 18. The catheter of claim 1, wherein the neuromodulation element defines a distally tapering tip.
  • 19. The catheter of claim 1, wherein the elongate shaft further comprises an intermediate segment distal to the proximal segment, the neuromodulation element being operably connected to a distal end of the intermediate segment.
  • 20. The catheter of claim 19, wherein the catheter further comprises electrical leads electrically connected to the electrodes, wherein the elongate shaft further comprises an electrically insulative tube and a guidewire tube disposed within the proximal segment, the electrical leads extending longitudinally through the electrically insulative tube.
  • 21. The catheter of claim 20, wherein the proximal segment defines a distal skive, the electrically insulative tube and the guidewire tube extending distally beyond the distal skive.
  • 22. The catheter of claim 21, wherein a proximal end of the intermediate segment is positioned at a region of the elongate shaft at which the electrically insulative tube and the guidewire tube distally emerge from the proximal segment, the electrically insulative tube and the guidewire tube extending at least partially through the intermediate segment.
  • 23. The catheter of claim 19, wherein the intermediate segment is more flexible than the proximal segment.
  • 24. The catheter of claim 19, wherein the intermediate segment comprises: an inner polymer layer;a metal braid; andat least one outer polymer layer, the metal braid being positioned between the inner polymer layer and the at least one outer polymer layer.
  • 25. The catheter of claim 1, wherein the proximal segment comprises a hypotube.
  • 26. A catheter comprising: an elongate shaft; anda neuromodulation element connected to the shaft, the neuromodulation element being movable from a low-profile delivery state to a radially expanded deployed state more helical than the delivery state, an outer perimeter of the neuromodulation element comprising a plurality of reduced-diameter segments spaced apart along a longitudinal axis of the neuromodulation element, wherein each reduced-diameter segment of the plurality of reduced-diameter segments has a smaller outer diameter than an outer diameter of an adjoining portion of the outer perimeter of the neuromodulation element,the neuromodulation element comprising a plurality of electrodes, each electrode of the plurality being seated in a respective reduced-diameter segment of the plurality of reduced-diameter segments, wherein the outer perimeter of the neuromodulation element comprises an outer surface of each electrode.
  • 27. The catheter of claim 26, wherein the plurality of electrodes comprise band electrodes.
  • 28. The catheter of claim 26, wherein the outer surface of each electrode is generally flush with the outer perimeter of the neuromodulation element between the reduced-diameter segments.
  • 29. The catheter of claim 26, wherein the elongate shaft comprises a proximal segment and an intermediate segment distal to the proximal segment, the neuromodulation element comprising a distal segment connected to a distal end of the intermediate segment, the distal segment being configured to have a first shape when the neuromodulation element is in the delivery state and a second shape when the neuromodulation element is in the deployed state, the second shape being more helical than the first shape.
  • 30. The catheter of claim 29, wherein the proximal segment comprises a hypotube, and wherein an inner diameter of each electrode is smaller than a maximum outer diameter of the neuromodulation element between the reduced-diameter segments.
CROSS-REFERENCE TO RELATED APPLICATION(S)

This application is a continuation of U.S. patent application Ser. No. 14/606,821, filed on Jan. 27, 2015, and entitled, “NEUROMODULATION CATHETERS HAVING JACKETED NEUROMODULATION ELEMENTS AND RELATED DEVICES, SYSTEMS, AND METHODS,” which claims the benefit of U.S. Provisional Patent Application No. 61/932,224, filed on Jan. 27, 2014, the disclosure of each which is incorporated herein by reference in its entirety.

US Referenced Citations (449)
Number Name Date Kind
4602624 Naples et al. Jul 1986 A
4649936 Ungar et al. Mar 1987 A
4709698 Johnston et al. Dec 1987 A
4764504 Johnson et al. Aug 1988 A
4890623 Cook et al. Jan 1990 A
4976711 Parins et al. Dec 1990 A
4998923 Samson et al. Mar 1991 A
5158564 Schnepp-Pesch et al. Oct 1992 A
5300068 Rosar et al. Apr 1994 A
5322064 Lundquist Jun 1994 A
5358514 Schulman et al. Oct 1994 A
5368591 Lennox et al. Nov 1994 A
5368592 Stern et al. Nov 1994 A
5399164 Snoke et al. Mar 1995 A
5423744 Gencheff et al. Jun 1995 A
5433742 Willis Jul 1995 A
5441483 Avitall Aug 1995 A
5445148 Jaraczewski et al. Aug 1995 A
5454788 Walker et al. Oct 1995 A
5477856 Lundquist Dec 1995 A
5484400 Edwards et al. Jan 1996 A
5545200 Nguyen et al. Aug 1996 A
5554114 Wallace et al. Sep 1996 A
5558643 Samson et al. Sep 1996 A
5571147 Sluijter et al. Nov 1996 A
5582609 Swanson et al. Dec 1996 A
5588964 Imran et al. Dec 1996 A
5599345 Edwards et al. Feb 1997 A
5626576 Janssen May 1997 A
5628775 Jackson et al. May 1997 A
5672174 Gough et al. Sep 1997 A
5688266 Edwards et al. Nov 1997 A
5695506 Pike et al. Dec 1997 A
5697928 Walcott et al. Dec 1997 A
5700282 Zabara Dec 1997 A
5707400 Terry, Jr. et al. Jan 1998 A
5709874 Hanson et al. Jan 1998 A
5741429 Donadio, III et al. Apr 1998 A
5743903 Stern et al. Apr 1998 A
5772590 Webster, Jr. Jun 1998 A
5807249 Qin et al. Sep 1998 A
5823955 Kuck et al. Oct 1998 A
5827272 Breining et al. Oct 1998 A
5860974 Abele Jan 1999 A
5865787 Shapland Feb 1999 A
5871444 Ouchi Feb 1999 A
5891114 Chien et al. Apr 1999 A
5893885 Webster, Jr. Apr 1999 A
5895378 Berenstein et al. Apr 1999 A
5904667 Falwell May 1999 A
5916214 Cosio et al. Jun 1999 A
5931830 Jacobsen et al. Aug 1999 A
5935102 Bowden et al. Aug 1999 A
5935124 Klumb et al. Aug 1999 A
5944710 Dev et al. Aug 1999 A
5951539 Nita et al. Sep 1999 A
5954719 Chen et al. Sep 1999 A
5961511 Mortier et al. Oct 1999 A
5967978 Littmann et al. Oct 1999 A
5971975 Mills et al. Oct 1999 A
5980563 Tu et al. Nov 1999 A
5983141 Sluijter et al. Nov 1999 A
5987344 West Nov 1999 A
6004269 Crowley et al. Dec 1999 A
6009877 Edwards Jan 2000 A
6024740 Lesh et al. Feb 2000 A
6036687 Laufer et al. Mar 2000 A
6048338 Larson et al. Apr 2000 A
6066134 Eggers et al. May 2000 A
6079414 Roth Jun 2000 A
6080171 Keith et al. Jun 2000 A
6090104 Webster Jul 2000 A
6091995 Ingle et al. Jul 2000 A
6099524 Lipson et al. Aug 2000 A
6102890 Stlyland et al. Aug 2000 A
6110187 Donlon Aug 2000 A
6117101 Diederich et al. Sep 2000 A
6135999 Fanton et al. Oct 2000 A
6142993 Whayne et al. Nov 2000 A
6149620 Baker et al. Nov 2000 A
6159187 Park et al. Dec 2000 A
6161048 Sluijter et al. Dec 2000 A
6165163 Chien et al. Dec 2000 A
6210362 Ponzi Apr 2001 B1
6210406 Webster Apr 2001 B1
6219577 Brown, III et al. Apr 2001 B1
6224592 Eggers et al. May 2001 B1
6245020 Moore et al. Jun 2001 B1
6245045 Stratienko Jun 2001 B1
6246912 Sluijter et al. Jun 2001 B1
6246914 De La Rama et al. Jun 2001 B1
6254588 Jones et al. Jul 2001 B1
6263224 West Jul 2001 B1
6273876 Klima et al. Aug 2001 B1
6273886 Edwards et al. Aug 2001 B1
6283951 Flaherty et al. Sep 2001 B1
6283960 Ashley Sep 2001 B1
6287301 Thompson et al. Sep 2001 B1
6292695 Webster, Jr. et al. Sep 2001 B1
6293943 Panescu et al. Sep 2001 B1
6298256 Meyer Oct 2001 B1
6299623 Wulfman Oct 2001 B1
6314325 Fitz Nov 2001 B1
6322558 Taylor et al. Nov 2001 B1
6322559 Daulton et al. Nov 2001 B1
6346074 Roth Feb 2002 B1
6371965 Gifford, III et al. Apr 2002 B2
6387105 Gifford, III et al. May 2002 B1
6401720 Stevens et al. Jun 2002 B1
6405732 Edwards et al. Jun 2002 B1
6413255 Stern Jul 2002 B1
6427089 Knowlton Jul 2002 B1
6443965 Gifford, III et al. Sep 2002 B1
6451034 Gifford, III et al. Sep 2002 B1
6454775 Demarais et al. Sep 2002 B1
6482202 Goble et al. Nov 2002 B1
6488679 Swanson et al. Dec 2002 B1
6491705 Gifford, III et al. Dec 2002 B2
6497711 Plaia et al. Dec 2002 B1
6500172 Panescu et al. Dec 2002 B1
6506189 Rittman et al. Jan 2003 B1
6508804 Sarge et al. Jan 2003 B2
6514226 Levin et al. Feb 2003 B1
6514236 Stratienko Feb 2003 B1
6517572 Kugler et al. Feb 2003 B2
6522926 Kieval et al. Feb 2003 B1
6542781 Koblish et al. Apr 2003 B1
6549800 Atalar et al. Apr 2003 B1
6562034 Edwards et al. May 2003 B2
6565582 Gifford, III et al. May 2003 B2
6569177 Dillard et al. May 2003 B1
6585718 Hayzelden et al. Jul 2003 B2
6610046 Usami et al. Aug 2003 B1
6611720 Hata et al. Aug 2003 B2
6613046 Jenkins et al. Sep 2003 B1
6616624 Kieval Sep 2003 B1
6622731 Daniel et al. Sep 2003 B2
6628976 Fuimaono et al. Sep 2003 B1
6632193 Davison et al. Oct 2003 B1
6635054 Fjield et al. Oct 2003 B2
6640120 Swanson et al. Oct 2003 B1
6648854 Patterson et al. Nov 2003 B1
6651672 Roth Nov 2003 B2
6656195 Peters et al. Dec 2003 B2
6659981 Stewart et al. Dec 2003 B2
6669670 Muni et al. Dec 2003 B1
6669692 Nelson et al. Dec 2003 B1
6676678 Gifford, III et al. Jan 2004 B2
6679268 Stevens et al. Jan 2004 B2
6682541 Gifford, III et al. Jan 2004 B1
6685648 Flaherty et al. Feb 2004 B2
6695857 Gifford Feb 2004 B2
6699257 Gifford, III et al. Mar 2004 B2
6702811 Stewart et al. Mar 2004 B2
6706010 Miki et al. Mar 2004 B1
6711444 Koblish Mar 2004 B2
6716207 Farnholtz Apr 2004 B2
6723043 Kleernan et al. Apr 2004 B2
6736835 Pellegrino et al. May 2004 B2
6745080 Koblish Jun 2004 B2
6749560 Konstorum et al. Jun 2004 B1
6752805 Maguire et al. Jun 2004 B2
6770070 Balbierz Aug 2004 B1
6790206 Panescu Sep 2004 B2
6829497 Mogul Dec 2004 B2
6830568 Kesten et al. Dec 2004 B1
6845267 Harrison et al. Jan 2005 B2
6849075 Bertolero et al. Feb 2005 B2
6850801 Kieval et al. Feb 2005 B2
6869431 Maguire et al. Mar 2005 B2
6884260 Kugler et al. Apr 2005 B2
6885888 Rezai Apr 2005 B2
6889694 Hooven May 2005 B2
6890329 Carroll et al. May 2005 B2
6893436 Woodard et al. May 2005 B2
6909009 Koridze Jun 2005 B2
6915806 Pacek et al. Jul 2005 B2
6917834 Koblish et al. Jul 2005 B2
6923808 Taimisto Aug 2005 B2
6926669 Stewart et al. Aug 2005 B1
6926713 Rioux et al. Aug 2005 B2
6939346 Kannenberg et al. Sep 2005 B2
6945956 Waldhauser et al. Sep 2005 B2
6949097 Stewart et al. Sep 2005 B2
6955175 Stevens et al. Oct 2005 B2
6966908 Maguire et al. Nov 2005 B2
6984238 Gifford, III et al. Jan 2006 B2
7058456 Pierce Jun 2006 B2
7087051 Bourne et al. Aug 2006 B2
7100614 Stevens et al. Sep 2006 B2
7102151 Reinberg et al. Sep 2006 B2
7110828 Kolberg et al. Sep 2006 B2
7112211 Gifford, III et al. Sep 2006 B2
7115183 Larson Oct 2006 B2
7137990 Hebert et al. Nov 2006 B2
7149574 Yun et al. Dec 2006 B2
7153315 Miller Dec 2006 B2
7162303 Levin et al. Jan 2007 B2
7172610 Heitzmann et al. Feb 2007 B2
7184811 Phan et al. Feb 2007 B2
7192427 Chapelon et al. Mar 2007 B2
7221979 Zhou et al. May 2007 B2
7238184 Megerman et al. Jul 2007 B2
7241273 Maguire et al. Jul 2007 B2
7276062 McDaniel et al. Oct 2007 B2
7294127 Leung et al. Nov 2007 B2
7311705 Sra Dec 2007 B2
7338467 Lutter Mar 2008 B2
7367972 Francischelli et al. May 2008 B2
7381200 Katoh et al. Jun 2008 B2
7390894 Weinshilboum et al. Jun 2008 B2
7393338 Nita Jul 2008 B2
7402151 Rosenman et al. Jul 2008 B2
7486805 Krattiger Feb 2009 B2
7488338 Eidenschink Feb 2009 B2
7494486 Mische et al. Feb 2009 B2
7494488 Weber et al. Feb 2009 B2
7497858 Chapelon et al. Mar 2009 B2
7517349 Truckai et al. Apr 2009 B2
7520863 Grewe et al. Apr 2009 B2
7540865 Griffin et al. Jun 2009 B2
7563247 Maguire et al. Jul 2009 B2
7617005 Demarais et al. Nov 2009 B2
7620451 Demarais et al. Nov 2009 B2
7637903 Lentz et al. Dec 2009 B2
7647115 Levin et al. Jan 2010 B2
7653438 Deem et al. Jan 2010 B2
7682319 Martin et al. Mar 2010 B2
7699809 Urmey Apr 2010 B2
7706894 Stewart et al. Apr 2010 B2
7708704 Mitelberg et al. May 2010 B2
7717853 Nita May 2010 B2
7717948 Demarais et al. May 2010 B2
7727187 Lentz Jun 2010 B2
7758520 Griffin et al. Jul 2010 B2
7763012 Petrick et al. Jul 2010 B2
7771410 Venturelli Aug 2010 B2
7771421 Stewart et al. Aug 2010 B2
7778703 Gross et al. Aug 2010 B2
7780660 Bourne et al. Aug 2010 B2
7785289 Rios et al. Aug 2010 B2
7806871 Li et al. Oct 2010 B2
7811265 Hering et al. Oct 2010 B2
7811281 Rentrop Oct 2010 B1
7815637 Ormsby et al. Oct 2010 B2
7819866 Bednarek Oct 2010 B2
7846157 Kozel Dec 2010 B2
7850685 Kunis et al. Dec 2010 B2
7862565 Eder et al. Jan 2011 B2
7863897 Slocum, Jr. et al. Jan 2011 B2
7896873 Hiller et al. Mar 2011 B2
7905862 Sampson Mar 2011 B2
7938830 Saadat et al. May 2011 B2
7967816 Ocel et al. Jun 2011 B2
7989042 Obara et al. Aug 2011 B2
8007440 Magnin et al. Aug 2011 B2
8007462 Gibson et al. Aug 2011 B2
8027718 Spinner et al. Sep 2011 B2
8043288 Dando et al. Oct 2011 B2
8075580 Makower Dec 2011 B2
8088127 Mayse et al. Jan 2012 B2
8092444 Lentz et al. Jan 2012 B2
8124876 Dayton et al. Feb 2012 B2
8131371 Demarais et al. Mar 2012 B2
8131372 Levin et al. Mar 2012 B2
8140170 Rezai et al. Mar 2012 B2
8145317 Demarais et al. Mar 2012 B2
8150518 Levin et al. Apr 2012 B2
8150519 Demarais et al. Apr 2012 B2
8150520 Demarais et al. Apr 2012 B2
8172829 Farnholtz May 2012 B2
8175711 Demarais et al. May 2012 B2
8190238 Moll et al. May 2012 B2
8241217 Chiang et al. Aug 2012 B2
8251977 Partlett Aug 2012 B2
8292881 Brannan et al. Oct 2012 B2
8343145 Brannan Jan 2013 B2
8366615 Razavi Feb 2013 B2
8376865 Forster et al. Feb 2013 B2
8388680 Starksen et al. Mar 2013 B2
8398629 Thistle Mar 2013 B2
8401650 Simon et al. Mar 2013 B2
8409193 Young et al. Apr 2013 B2
8409195 Young Apr 2013 B2
8418362 Zerfas et al. Apr 2013 B2
8473023 Worley et al. Jun 2013 B2
8485992 Griffin et al. Jul 2013 B2
8486060 Kotmel et al. Jul 2013 B2
8486063 Werneth et al. Jul 2013 B2
8740849 Fischell et al. Jun 2014 B1
8817999 Moeller et al. Aug 2014 B2
8974451 Smith Mar 2015 B2
9162046 Hill et al. Oct 2015 B2
10166069 Tran Jan 2019 B2
20020022864 Mahvi et al. Feb 2002 A1
20020062123 McClurken et al. May 2002 A1
20020087208 Koblish et al. Jul 2002 A1
20020107515 Edwards et al. Aug 2002 A1
20020139379 Edwards et al. Oct 2002 A1
20020165532 Hill, III et al. Nov 2002 A1
20020183682 Darvish et al. Dec 2002 A1
20030004510 Wham et al. Jan 2003 A1
20030050635 Truckai et al. Mar 2003 A1
20030050681 Pianca et al. Mar 2003 A1
20030060858 Kieval et al. Mar 2003 A1
20030065317 Rudie et al. Apr 2003 A1
20030074039 Puskas Apr 2003 A1
20030092995 Thompson May 2003 A1
20030125790 Fastovsky et al. Jul 2003 A1
20030139689 Shturman et al. Jul 2003 A1
20030181897 Thomas et al. Sep 2003 A1
20030195507 Stewart et al. Oct 2003 A1
20030199863 Swanson et al. Oct 2003 A1
20030216792 Levin et al. Nov 2003 A1
20030220639 Chapelon et al. Nov 2003 A1
20030229340 Sherry et al. Dec 2003 A1
20030233099 Danaek et al. Dec 2003 A1
20040006359 Laguna Jan 2004 A1
20040010289 Biggs et al. Jan 2004 A1
20040030375 Pierce Feb 2004 A1
20040073206 Foley et al. Apr 2004 A1
20040088002 Boyle et al. May 2004 A1
20040167509 Taimisto Aug 2004 A1
20040215186 Cornelius et al. Oct 2004 A1
20050004515 Hart et al. Jan 2005 A1
20050010095 Stewart et al. Jan 2005 A1
20050080409 Young et al. Apr 2005 A1
20050096647 Steinke et al. May 2005 A1
20050187579 Danek et al. Aug 2005 A1
20050228286 Messerly et al. Oct 2005 A1
20050228460 Levin et al. Oct 2005 A1
20050273006 Stewart et al. Dec 2005 A1
20060004323 Chang et al. Jan 2006 A1
20060004346 Begg Jan 2006 A1
20060025765 Landman et al. Feb 2006 A1
20060074403 Rafiee Apr 2006 A1
20060085054 Zikorus et al. Apr 2006 A1
20060089637 Werneth et al. Apr 2006 A1
20060095029 Young et al. May 2006 A1
20060122587 Sharareh Jun 2006 A1
20060142753 Francischelli et al. Jun 2006 A1
20060167498 DiLorenzo Jul 2006 A1
20060184221 Stewart et al. Aug 2006 A1
20060206150 Demarais et al. Sep 2006 A1
20060212076 Demarais et al. Sep 2006 A1
20060224153 Fischell et al. Oct 2006 A1
20060263393 Demopulos et al. Nov 2006 A1
20060271111 Demarais et al. Nov 2006 A1
20060276846 Malecki et al. Dec 2006 A1
20060287644 Inganas et al. Dec 2006 A1
20070027390 Maschke et al. Feb 2007 A1
20070049924 Rahn Mar 2007 A1
20070067008 Scheiner et al. Mar 2007 A1
20070073151 Lee Mar 2007 A1
20070100405 Thompson et al. May 2007 A1
20070106247 Burnett et al. May 2007 A1
20070112327 Yun et al. May 2007 A1
20070129720 Demarais et al. Jun 2007 A1
20070149963 Matsukuma et al. Jun 2007 A1
20070156114 Worley et al. Jul 2007 A1
20070179496 Swoyer et al. Aug 2007 A1
20070197891 Shachar et al. Aug 2007 A1
20070265687 Deem et al. Nov 2007 A1
20070270779 Jacobs et al. Nov 2007 A1
20080004658 Malecki et al. Jan 2008 A1
20080015562 Hong et al. Jan 2008 A1
20080071269 Hilario et al. Mar 2008 A1
20080077119 Snyder et al. Mar 2008 A1
20080086047 McDaniel et al. Apr 2008 A1
20080091193 Kauphusman et al. Apr 2008 A1
20080108867 Zhou May 2008 A1
20080140072 Stangenes et al. Jun 2008 A1
20080177205 Rama et al. Jul 2008 A1
20080287918 Rosenman et al. Nov 2008 A1
20080319513 Pu et al. Dec 2008 A1
20090012465 Latini Jan 2009 A1
20090030312 Hadjicostis Jan 2009 A1
20090036948 Levin et al. Feb 2009 A1
20090043372 Northrop et al. Feb 2009 A1
20090069671 Anderson Mar 2009 A1
20090118620 Tgavalekos et al. May 2009 A1
20090149848 Werneth et al. Jun 2009 A1
20090157048 Sutermeister et al. Jun 2009 A1
20090163850 Betts et al. Jun 2009 A1
20090171333 Hon Jul 2009 A1
20090221955 Babaev Sep 2009 A1
20090306650 Govari et al. Dec 2009 A1
20090312606 Dayton et al. Dec 2009 A1
20100030061 Canfield et al. Feb 2010 A1
20100069882 Jennings et al. Mar 2010 A1
20100137860 Demarais et al. Jun 2010 A1
20100137952 Demarais et al. Jun 2010 A1
20100168740 Stewart et al. Jul 2010 A1
20100179512 Chong et al. Jul 2010 A1
20100191112 Demarais et al. Jul 2010 A1
20100217184 Koblish et al. Aug 2010 A1
20100222851 Deem et al. Sep 2010 A1
20100222854 Demarais et al. Sep 2010 A1
20100249604 Hastings et al. Sep 2010 A1
20100312141 Keast et al. Dec 2010 A1
20100324482 Farnholtz Dec 2010 A1
20110021976 Li et al. Jan 2011 A1
20110028962 Werneth et al. Feb 2011 A1
20110034989 Al-Marashi et al. Feb 2011 A1
20110054464 Werneth et al. Mar 2011 A1
20110054465 Werneth et al. Mar 2011 A1
20110071400 Hastings et al. Mar 2011 A1
20110071401 Hastings et al. Mar 2011 A1
20110112476 Kauphusman et al. May 2011 A1
20110270173 Gibson et al. Nov 2011 A1
20120059241 Hastings et al. Mar 2012 A1
20120130289 Demarais et al. May 2012 A1
20120130345 Levin et al. May 2012 A1
20120172837 Demarais et al. Jul 2012 A1
20120197246 Mauch Aug 2012 A1
20120265066 Crow et al. Oct 2012 A1
20130035681 Subramaniam et al. Feb 2013 A1
20130090647 Smith Apr 2013 A1
20130090649 Smith et al. Apr 2013 A1
20130090651 Smith Apr 2013 A1
20130090652 Jenson Apr 2013 A1
20130096550 Hill Apr 2013 A1
20130096553 Hill et al. Apr 2013 A1
20130096554 Groff et al. Apr 2013 A1
20130123770 Smith May 2013 A1
20130131667 Jenson et al. May 2013 A1
20130150808 Ogle et al. Jun 2013 A1
20130172879 Sutermeister et al. Jul 2013 A1
20130172881 Hill et al. Jul 2013 A1
20130184642 O'Donnell et al. Jul 2013 A1
20130184703 Shireman et al. Jul 2013 A1
20130237780 Beasley et al. Sep 2013 A1
20130274730 Anderson et al. Oct 2013 A1
20130274731 Anderson et al. Oct 2013 A1
20130274737 Wang et al. Oct 2013 A1
20130304061 Chang et al. Nov 2013 A1
20140094787 Reynolds Apr 2014 A1
20140121641 Fischell et al. May 2014 A1
20140121644 Fischell et al. May 2014 A1
20140135755 Sutermeister et al. May 2014 A1
20140214026 Degen Jul 2014 A1
20140249524 Kocur Sep 2014 A1
20140276613 Goodman et al. Sep 2014 A1
20140276752 Wang et al. Sep 2014 A1
20140276787 Wang et al. Sep 2014 A1
20140358079 Fischell et al. Dec 2014 A1
20140378967 Willard et al. Dec 2014 A1
20150265339 Lindquist et al. Sep 2015 A1
20180042672 Heisel et al. Feb 2018 A1
Foreign Referenced Citations (118)
Number Date Country
2782017 May 2006 CN
201375561 Jan 2010 CN
102125460 Jul 2011 CN
102125725 Jul 2011 CN
102885648 Jan 2013 CN
102885649 Jan 2013 CN
102908188 Feb 2013 CN
102908189 Feb 2013 CN
102005041601 Apr 2007 DE
102012104705 Dec 2013 DE
0348136 Dec 1989 EP
0352955 Jan 1990 EP
0647435 Apr 1995 EP
0652026 May 1995 EP
0664990 Aug 1995 EP
0680351 Nov 1995 EP
0512359 Dec 1996 EP
0787019 Aug 1997 EP
0542246 Sep 1997 EP
0834289 Apr 1998 EP
0862478 Sep 1998 EP
0937481 Aug 1999 EP
0944353 Sep 1999 EP
0951244 Oct 1999 EP
0984806 Mar 2000 EP
0626818 May 2002 EP
0727184 Dec 2002 EP
1286625 Mar 2003 EP
1374943 Jan 2004 EP
1656963 May 2006 EP
1709922 Oct 2006 EP
1768732 Apr 2007 EP
1787674 May 2007 EP
1824548 Aug 2007 EP
1827558 Sep 2007 EP
1857134 Nov 2007 EP
1906853 Apr 2008 EP
1968679 Sep 2008 EP
2027882 Feb 2009 EP
1326550 Sep 2009 EP
2320821 May 2011 EP
2340765 Jul 2011 EP
2389974 Nov 2011 EP
2398540 Dec 2011 EP
2445568 May 2012 EP
2747688 Jul 2014 EP
2759314 Jul 2014 EP
2804554 Nov 2014 EP
2900160 Aug 2015 EP
2900161 Aug 2015 EP
2990070 Mar 2016 EP
3010436 Apr 2016 EP
2768563 Nov 2016 EP
WO1991001772 Feb 1991 WO
WO1992015356 Sep 1992 WO
WO1994007446 Apr 1994 WO
WO1994019039 Sep 1994 WO
WO1994028809 Dec 1994 WO
WO1995025472 Sep 1995 WO
WO1995031142 Nov 1995 WO
WO1997029800 Aug 1997 WO
WO1997036548 Oct 1997 WO
WO1997048435 Dec 1997 WO
WO1998042403 Oct 1998 WO
WO 1998043530 Oct 1998 WO
WO1998048885 Nov 1998 WO
WO 1998050098 Nov 1998 WO
WO1998052637 Nov 1998 WO
WO1999000060 Jan 1999 WO
WO1999011313 Mar 1999 WO
WO2001022897 Apr 2001 WO
WO2001037723 May 2001 WO
WO2001037746 May 2001 WO
WO2001070114 Sep 2001 WO
WO2002030310 Apr 2002 WO
WO2002080766 Oct 2002 WO
WO2002089908 Nov 2002 WO
WO2003022167 Mar 2003 WO
WO2003082080 Oct 2003 WO
WO2014036163 Mar 2004 WO
WO2005030072 Apr 2005 WO
WO2005041748 May 2005 WO
WO2005110528 Nov 2005 WO
WO2006009588 Jan 2006 WO
WO2006041881 Apr 2006 WO
WO2006065949 Jun 2006 WO
WO2006105121 Oct 2006 WO
WO2007008954 Jan 2007 WO
WO2007059277 May 2007 WO
WO2007078997 Jul 2007 WO
WO2007117359 Oct 2007 WO
WO2008010150 Jan 2008 WO
WO2008036281 Mar 2008 WO
WO2008049084 Apr 2008 WO
WO2008064399 Jun 2008 WO
WO2008101244 Aug 2008 WO
WO2008139347 Nov 2008 WO
WO2009082635 Jul 2009 WO
WO2009088678 Jul 2009 WO
WO2009137819 Nov 2009 WO
WO2010091701 Aug 2010 WO
WO2010134503 Nov 2010 WO
WO2011056311 May 2011 WO
WO2012100095 Jul 2012 WO
WO2013016203 Jan 2013 WO
WO2013055537 Apr 2013 WO
WO2013055685 Apr 2013 WO
WO2013055815 Apr 2013 WO
WO2013055826 Apr 2013 WO
WO2013056672 Apr 2013 WO
WO2013058962 Apr 2013 WO
WO2013106054 Jul 2013 WO
WO2013109318 Jul 2013 WO
WO2013158676 Oct 2013 WO
WO2013158678 Oct 2013 WO
WO2014012282 Jan 2014 WO
WO2014174662 Oct 2014 WO
WO2016090175 Jun 2016 WO
Non-Patent Literature Citations (141)
Entry
Ahmed, Humera et al., Renal Sympathetic Denervation Using an Irrigated Radiofrequency Ablation Catheter for the Management of Drug-Resistant Hypertension, JACC Cardicvascular Interventions, vol. 5, No. 7, 2012, pp. 758-765.
Avetall et al., “The creation of linear contiguous lesions in the atria with an expandable loop catheter,” Journal of the American College of Cardiology, 1999; 33; pp. 972-984.
Beale et al., “Minimally Invasive Treatment for Varicose Veins: A Review of Endovenous Laser Treatment and Radiofrequency Ablation”. Lower Extremity Wounds 3(4), 2004, 10 pages.
Blessing, Erwin et al., Cardiac Ablation and Renal Denervation Systems Have Distinct Purposes and Different Technical Requirements, JACC Cardiovascular Interventions, vol. 6, No. 3, 2013, 1 page.
ClinicalTrials.gov, Renal Denervation in Patients with uncontrolled Hypertension in Chinese (2011), 6pages. www.clinicaltrials.gov/ct2/show/NCT01390831.
Dodge, et al., “Lumen Diameter of Normal Human Coronary Arteries Influence of Age, Sex, Anatomic Variation, and Left Ventricular Hypertrophy or Dilation”, Circulation, 1992, vol. 86 (1), pp. 232-246.
Excerpt of Operator's Manual of Boston Scientific's EPT-1000 XP Cardiac Ablation Controller & Accessories, Version of Apr. 2003, (6 pages).
Excerpt of Operator's Manual of Boston Scientific's Maestro 30000 Cardiac Ablation System, Version of Oct. 17, 2005 , (4 pages).
Holmes et al., Pulmonary Vein Stenosis Complicating Ablation for Atrial Fibrillation: Clinical Spectrum and Interventional Considerations, JACC: Cardiovascular Interventions, 2: 4, 2009, 10 pages.
Kandarpa, Krishna et al., “Handbook of Interventional Radiologic Procedures”, Third Edition, pp. 194-210 (2002).
Mount Sinai School of Medicine clinical trial for Impact of Renal Sympathetic Denervation of Chronic Hypertension, Mar. 2013, 11 pages. http://clinicaltrials.gov/ct2/show/NCT01628198.
Opposition to European Patent No. 2465470, Granted Oct. 28, 2015, Date of Opposition Jul. 27, 2016, 34 pp.
Opposition to European Patent No. EP1802370, Granted Jan. 5, 2011, Date of Opposition Oct. 5, 2011, 24 pages.
Opposition to European Patent No. EP2037840, Granted Dec. 7, 2011, Date of Opposition Sep. 7, 2012, 25 pages.
Opposition to European Patent No. EP2092957, Granted Jan. 5, 2011, Date of Opposition Oct. 5, 2011, 26 pages.
Oz, Mehmet, Pressure Relief, TIME, Jan. 9, 2012, 2 pages. <www.time.come/time/printout/0,8816,2103278,00.htm>.
Papademetriou, Vasillios, Renal Sympathetic Denervation for the Treatment of Difficult-to-Control or Resistant Hypertension, Int. Journal of Hypertension, 2011, 8 pages.
Pieper, et al., “Design and Implementation of a New Computerized System for Intraoperative Cardiac Mapping” Journal of Applied Physiology, 1991; vol. 71 (4), pp. 1529-1539.
Prochnau, Dirk et al., Catheter-based renal denervation for drug-resistant hypertension by using a standard electrophysiology catheter; Euro Intervention 2012, vol. 7, pp. 1077-1080.
Purerfellner, Helmut et al., Incidence, Management, and Outcome in Significant Pulmonary Vein Stenosis Complicating Ablation for Atrial Fibrillation, Am. J. Cardiol , 93, Jun. 1, 2004, 4 pages.
Purerfellner, Helmut et al., Pulmonary Vein Stenosis Following Catheter Ablation of Atrial Fibrillation, Curr. Opin. Cardio. 20 :484-490, 2005.
Remo, et al., “Safety and Efficacy of Renal Denervation as a Novel Treatment of Ventricular Tachycardia Storm in Patients with Cardiomyopathy” Heart Rhythm 2014, 11(4), pp. 541-546.
Schneider, Peter A., “Endovascular Skills—Guidewire and Catheter Skills for Endovascular Surgery,” Second Edition Revised and Expanded, 10 pages, (2003).
ThermaCool Irrigated Catheter and Integrated Ablation System, Biosense Webster (2006), 6 pages.
Tsao, Hsuan-Ming, Evaluation of Pulmonary Vein Stenosis after Catheter Ablation of Atrial Fibrillation, Cardiac Electrophysiology Review, 6, 2002, 4 pages.
U.S. Appl. No. 11/363,867, filed Feb. 27, 2006, 70 pp.
U.S. Appl. No. 60/813,589, filed Dec. 29, 2005, 62 pgs.
U.S. Appl. No. 60/852,787, filed Oct. 18, 2006, 112 pgs.
Ureter, https://en.wikipedia.org/wiki/Ureter, Jun. 2016, 6 pgs.
Wittkampf et al., “Control of radiofrequency lesion size by power regulation,” Journal of the American Heart Associate, 1989, 80: pp. 962-968.
Zheng et al., “Comparison of the temperature profile and pathological effect at unipolar, bipolar and phased radiofrequency current configurations,” Journal of Interventional Cardiac Electrophysiology, 2001, pp. 401-410.
U.S. Appl. No. 95/002,110, filed Aug. 29, 2012, Demarais et al.
U.S. Appl. No. 95/002,209, filed Sep. 13, 2012, Levin et al.
U.S. Appl. No. 95/002,233, filed Sep. 13, 2012, Levin et al.
U.S. Appl. No. 95/002,243, filed Sep. 13, 2012, Levin et al.
U.S. Appl. No. 95/002,253, filed Sep. 13, 2012, Demarais et al.
U.S. Appl. No. 95/002,255, filed Sep. 13, 2012, Demarais et al.
U.S. Appl. No. 95/002,292, filed Sep. 14, 2012, Demarais et al.
U.S. Appl. No. 95/002,327, filed Sep. 14, 2012, Demarais et al.
U.S. Appl. No. 95/002,335, filed Sep. 14, 2012, Demarais et al.
U.S. Appl. No. 95/002,336, filed Sep. 14, 2012, Levin et al.
U.S. Appl. No. 95/002,356, filed Sep. 14, 2012, Demarais et al.
“2011 Edison Award Winners,” Edison Awards: Honoring Innovations & Innovators, 2011, 6 pages, <http://www.edisonawards.com/BestNewProduct_2011.php>.
“2012 top 10 advances in heart disease and stroke research: American Heart Association/America Stroke Association Top 10 Research Report.” American Heart Association, Dec. 17, 2012, 5 pages, <http://newsroom.heart.org/news/2012-top-10-advances-in-heart-241901>.
“Ardian(R) Receives 2010 EuroPCR Innovation Award and Demonstrates Further Durability of Renal Denervation Treatment for Hypertension.” PR Newswire, Jun. 3, 2010, 2 pages, <http://www.prnewswire.com/news-releases/ardianr-receives-2010-europcr-innovation-award-and-demonstrates-further-durability-of-renal-denervation-treatment-for-hypertension-95545014.html>.
“Boston Scientific to Acquire Vessix Vascular, Inc.: Company to Strengthen Hypertension Program with Acquisition of Renal Denervation Technology.” Boston Scientific: Advancing science for life—Investor Relations, Nov. 8, 2012, 2 pages, <http://phx.corporate-ir.net/phoenix.zhtml?c=62272&p=irol-newsArticle&id=1756108>.
“Cleveland Clinic Unveils Top 10 Medical Innovations for 2012: Experts Predict Ten Emerging Technologies that will Shape Health Care Next Year.” Cleveland Clinic, Oct. 6, 2011, 2 pages. <http://my.clevelandclinic.org/media_relations/library/2011/2011-10-6-cleveland-clinic-unveils-top-10-medical-innovations-for-2012.aspx>.
“Does renal represent a new treatment option for resistant hypertension?” Interventional News, Aug. 3, 2010, 2 pages. <http://www.cxvascular.com/in-latest-news/interventional-news—latest-news/does-renal-denervation-represent-a-new-treatment-option-for-resistant-hypertention>.
“Iberis—Renal Sympathetic Denervation System: Turning innovation into quality care.” [Brochure], Terumo Europe N.V., 2013, Europe, 3 pages.
“Neurotech Reports Announces Winners of Gold Electrode Awards.” Neurotech business report, 2009. 1 page. <http://www.neurotechreports.com/pages/goldelectrodes09.html>.
“Quick. Consistent. Controlled. OneShot renal Denervation System” [Brochure], Covidien: positive results for life, 2013, (n.l.), 4 pages.
“Renal Denervation Technology of Vessix Vascular, Inc. been acquired by Boston Scientific Corporation (BSX) to pay up to $425 Million.” Vessix Vascular Pharmaceutical Intelligence: A blog specializing in Pharmaceutical Intelligence and Analytics, Nov. 8, 2012, 21 pages, <http://pharmaceuticalintelligence.com/tag/vessix-vascular/>.
“The Edison Awards™” Edison Awards: Honoring Innovations & Innovators, 2013, 2 pages, <http://www.edisonawards.com/Awards.php>.
“The Future of Renal denervation for the Treatment of Resistant Hypertension.” St. Jude Medical, Inc., 2012, 12 pages.
“Vessix Renal Denervation System: So Advanced It's Simple.” [Brochure], Boston Scientific: Advancing science for life, 2013, 6 pages.
Asbell, Penny, “Conductive Keratoplasty for the Correction of Hyperopia.” Tr Am Ophth Soc, 2001, vol. 99, 10 pages.
Badoer, Emilio, “Cardiac afferents play the dominant role in renal nerve inhibition elicited by volume expansion in the rabbit.” Am J Physiol Regul Intergr Comp Physiol, vol. 274, 1998, 7 pages.
Bengel, Frank, “Serial Assessment of Sympathetic Reinnervation After Orthotopic Heart Transplation: A logitudinal Study Using PET and C-11 Hydroxyephedrine.” Circulation, vol. 99, 1999, 7 pages.
Benito, F., et al. “Radiofrequency catheter ablation of accessory pathways in infants.” Heart, 78:160-162 (1997).
Bettmann, Michael, Carotid Stenting and Angioplasty: A Statement for Healthcare Professionals from the Councils on Cardiovascular Radiology, Stroke, Cardio-Thoracic and Vascular Surgery, Epidemiology and Prevention, and Clinical Cardiology, American Heart Association, Circulation, vol. 97, 1998, 4 pages.
Bohm, Michael et al., “Rationale and design of a large registry on renal denervation: the Global Symplicity registry.” EuroIntervention, vol. 9, 2013, 9 pages.
Brosky, John, “EuroPCR 2013: CE-approved devices line up for renal denervation approval.” Medical Device Daily, May 28, 2013, 3 pages, <http://www.medicaldevicedaily.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid83002>.
Davis, Mark et al., “Effectiveness of Renal Denervation Therapy for Resistant Hypertension.” Journal of the American College of Cardiology, vol. 62, No. 3, 2013, 11 pages.
Dubuc, M., et al., “Feasibility of cardiac cryoablation using a transvenous steerable electrode catheter.” J Interv Cardiac Electrophysiol, 2:285-292 (1998).
Final Office Action; U.S. Appl. No. 12/827,700; dated Feb. 5, 2013, 61 pages.
Geisler, Benjamin et al., “Cost-Effectiveness and Clinical Effectiveness of Catheter-Based Renal Denervation for Resistant Hypertension.” Journal of the American College of Cardiology, col. 60, No. 14, 2012, 7 pages.
Gelfand, M., et al., “Treatment of renal failure and hypertension.” U.S. Appl. No. 60/442,970, filed Jan. 29, 2003, 23 pages.
Gertner, Jon, “Meet the Tech Duo That's Revitalizing The Medical Device Industry.” Fast Company, Apr. 15, 2013, 6:00 AM, 17 pages, <http://www.fastcompany.com/3007845/rneet-tech-duo-thats-revitalizing-medical-device-industry>.
Golwyn, D. H., Jr., et al. “Percutaneous Transcatheter Renal Ablation with Absolute Ethanol for Uncontrolled Hypertension or Nephrotic Syndrome: Results in 11 Patients with End-Stage Renal Disease.” JVIR, 8: 527-533 (1997).
Hall, W. H., et al. “Combined embolization and percutaneous radiofrequency ablation of a solid renal tumor.” Am. J. Roentgenol,174: 1592-1594 (2000).
Han, Y.-M, et al., “Renal artery embolization with diluted hot contrast medium: An experimental study,” J Vasc Interv Radiol, 12: 862-868 (2001).
Hansen, J. M., et al. “The transplanted human kidney does not achieve functional reinnervation.” Clin. Sci, 87: 13-19 (1994).
Hendee, W. R. et al. “Use of Animals in Biomedical Research: The Challenge and Response.” American Medical Association White Paper (1988) 39 pages.
Hering, Dagmara et al., “Chronic kidney disease: role of sympathetic nervous system activation and potential benefits of renal denervation.” EuroIntervention, vol. 9, 2013, 9 pages.
Imimdtanz, “Medtronic awarded industry's highest honor for renal denervation system.” The official blog of Medtronic Australasia, Nov. 12, 2012, 2 pages, <http://97waterlooroad.wordpress.com/2012/11/12/medtronic-awarded-industrys-highest-honour-for-renal-denervation-systems/>.
Kaiser, Chris, AHA Lists Year's Big Advances in CV Research, medpage Today, Dec. 18, 2012, 4 pages, <http://www.medpagetoday.com/Cardiology/PCI/36509>.
Kompanowska, E., et al., “Early Effects of renal denervation in the anaesthetised rat: Natriuresis and increased cortical blood flow.” J Physiol, 531. 2:527-534 (2001).
Lee, S. J., et al. “Ultrasonic energy in endoscopic surgery.” Yonsei Med J, 40:545-549 (1999).
Linz, Dominik et al., “Renal denervation suppresses ventricular arrhythmias during acute ventricular ischemia in pigs.” Heart Rhythm, vol. 0, No. 0, 2013, 6 pages.
Lustgarten, D. L., et al., “Cryothermal ablation: Mechanism of tissue injury and current experience in the treatment of tachyarrhythmias.” Progr Cardiovasc Dis, 41:481-498 (1999).
Mabin, Tom et al., “First experience with endovascular ultrasound renal denervation for the treatment of resistant hypertension.” EuroIntervention, vol. 8, 2012, 5 pages.
Mahfoud, Felix et al., “Ambulatory Blood Pressure Changes after Renal Sympathetic Denervation in Patients with Resistant Hypertension.” Circulation, 2013, 25 pages.
Mahfoud, Felix et al., “Expert consensus document from the European Society of Cardiology on catheter-based renal denervation.” European Heart Journal, 2013, 9 pages.
Mahfoud Felix et al., “Renal Hemodynamics and Renal Function After Catheter-Based Sympathetic Denervation in Patients With Resistant Hypertension.” Hypertension, 2012, 6 pages.
Medical-Dictionary.com, Definition of “Animal Model,” http://medical-dictionary.com (search “Animal Model”), 2005, 1 page.
Medtronic, Inc., Annual Report (Form 10-K) (Jun. 28, 2011) 44 pages.
Millard, F. C., et al, “Renal Embolization for ablation of function in renal failure and hypertension.” Postgraduate Medical Journal, 65, 729-734, (1989).
Oliveira, V., et al., “Renal denervation normalizes pressure and baroreceptor reflex in high renin hypertension in conscious rats.” Hypertension 19:II-17-II-21 (1992).
Ong, K. L., et al. “Prevalence, Awareness, Treatment, and Control of Hypertension Among United States Adults 1999-2004,” Hypertension, 49: 69-75 (2007) (originally published online Dec. 11, 2006).
Ormiston, John et al., “First-in-human use of the OneShot™ renal denervation system from Covidien.” EuroIntervention, vol. 8, 2013, 4 pages.
Ormiston, John et al., “Renal denervation for resistant hypertension using an irrigated radiofrequency balloon: 12-month results from the Renal Hypertension Ablation System (RHAS) trial,” EuroIntervention, vol. 9, 2013, 5 pages.
Pedersen, Amanda, “TCT 2012: Renal denervation device makers play show and tell.” Medical Device Daily, Oct. 26, 2012, 2 pages, <http://www.medicaldevicedaily.com/servlet/com.accumedia.web.Dispatcher?next=bioWorldHeadlines_article&forceid=80880>.
Peet, M., “Hypertension and its Surgical Treatment by bilateral supradiaphragmatic splanchnicectomy” Am J surgery (1948) pp. 48-68.
Renal Denervation (RDN), Symplicity RDN System Common Q&A (2011), 4 pages, http://www.medtronic.com/rdn/mediakit/RDN%20FAQ.pdf.
Schlaich, Markus et al., “Renal Denervation in Human Hypertension: Mechanisms, Current Findings, and Future Prospects.” Curr Hypertens Rep, vol. 14, 2012, 7 pages.
Schmid, Axel et al., “Does Renal Artery Supply Indicate Treatment Success of Renal Denervation.” Cardiovasc Intervent Radiol, vol. 36, 2013, 5 pages.
Schmieder, Roland E. et al., “Updated ESH position paper on interventional therapy of resistant hypertension.” EuroIntervention, vol. 9, 2013, 9 pages.
Sievert, Horst, “Novelity Award EuroPCR 2010.” Euro PCR, 2010, 15 pages.
Stella, A., et al., “Effects of reversible renal denervation on haemodynamic and excretory functions on the ipsilateral and contralateral kidney in the cat.” Hypertension, 4:181-188 (1986).
Stouffer, G.A. et al., “Catheter-based renal denervation in the treatment of resistant hypertension.” Journal of Molecular and Cellular Cardiology, vol. 62, 2013, 6 pages.
Swartz, J. F., et al., “Radiofrequency endocardial catheter ablation of accessory atrioventricular pathway atrial insertion sites.” Circulation, 87: 487-499 (1993).
Uchida, F., et al., “Effect of radiofrequency catheter ablation on parasympathetic denervation; A comparison of three different ablation sites.” PACE, 21:2517-2521 (1998).
Verloop, W. L. et al., “Renal denervation: a new treatment option in resistant arterial hypertension.” Neth Heart J., Nov. 30, 2012, 6 pages, <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547427/>.
Weinstock, M., et al., “Renal denervation prevents sodium retention and hypertension in salt sensitive rabbits with genetic baroreflex impairment.” Clinical Science, 90:287-293 (1996).
Wilcox, Josiah N., Scientific Basis Behind Renal Denervation for the Control of Hypertension, ICI 2012, Dec. 5-6, 2012. 38 pages.
Worthley, Stephen et al., “Safety and efficacy of a multi-electrode renal sympathetic denervation system in resistant hypertension: the EnligHTN I trial.” European Heart Journal, vol. 34, 2013, 9 pages.
Worthley, Stephen, “The St. Jude Renal Denervation System Technology and Clinical Review.” The University of Adelaide Australia, 2012, 24 pages.
Zuern, Christine S., “Impaired Cardiac Baroflex Sensitivity Predicts Response to Renal Sympathetic Denervation in Patients with Resistant Hypertension.” Journal of the American College of Cardiology, 2013, doi: 10.1016/j.jacc.2013.07.046, 24 pages.
Miller, Reed, “Finding a Future for Renal Denervation With Better Controlled Trials.” Pharma & Medtech Business Intelligence, Article # 01141006003, Oct. 6, 2014, 4 pages.
Papademetriou, Vasilios; “Renal Denervation and Symplicity HTN-3: “Dubium Sapientiae Initium” (Doubt is the Beginning of Wisdom)”, Circulation Research, 2014; 115: 211-214.
Papademetriou, Vasilios et al., “Renal Nerve Ablation for Resistant Hypertension: How Did We Get Here, Present Status, and Future Directions.” Circulation. 2014; 129: 1440-1450.
Papademetriou, Vasilios et al., “Catheter-Based Renal for Resistant Hypertension: 12-Month Results of the EnligHTN I First-in-Human Study Using a Multielectrode Ablation System.” Hypertension, 2014; 64: 565-572.
Doumas, Michael et al., “Renal Nerve ablation for Resistant Hypertension: The Dust Has Not Yet Settled,” The Journal of Clinical Hypertension, 2014; vol. 16, No. 6, 2 pages.
Messerli, Franz H. et al. “Renal Denervation for Resistant Hypertension: Dead or Alive?” Healio: Cardiology today's Intervention, May/Jun. 2014, 2 pages.
Allen, E.V., Sympathectomy for essential hypertension, Circulation, 1952, 6:131-140.
Bello-Reuss, E. et al., “Effects of Acute Unilateral Renal Denervation in the Rat,” Journal of Clinical Investigation, vol. 56, Jul. 1975, pp. 208-217.
Bello-Reuss, E. et al., “Effects of Renal Sympathetic Nerve Stimulation on Proximal Water and Sodium Reabsorption,” Journal of Clinical Investigation, vol. 57, Apr. 1976, pp. 1104-1107.
Bhandari, A. and Ellias, M., “Loin Pain Hematuria Syndrome: Pain Control with RFA to the Splanchanic Plexus,” The Pain Clinc, 2000, vol. 12, No. 4, pp. 323-327.
Curtis, John J. et al., “Surgical Therapy for Persistent Hypertension After Renal Transplantation” Transplantation, 31:125-128 (1981).
Dibona, Gerald F. et al., “Neural Control of Renal Function,” Physiological Reviews, vol. 77, No. 1, Jan. 1997, The American Physiological Society 1997, pp. 75-197.
Dibona, Gerald F., “Neural Control of the Kidney—Past, Present and Future,” Nov. 4, 2002, Novartis Lecture, Hypertension 2003, 41 part 2, 2002 American Heart Association, Inc., pp. 621-624.
Janssen, Ben J.A. et al., “Effects of Complete Renal Denervation and Selective Afferent Renal Denervation on the Hypertension Induced by Intrarenal Norepinephrine Infusion in Conscious Rats”, Journal of Hypertension 1989, 7: 447-455.
Katholi, Richard E., “Renal Nerves in the Pathogenesis of Hypertension in Experimental Animals and Humans,” Am J. Physiol. vol. 245, 1983, The American Physiological Society 1983, pp. F1-F14.
Krum, Henry et al., “Catheter-Based Renal Sympathetic Denervation for Resistant Hypertension: A Mulitcentre Safety and Proof-of Principle Cohort Study,” Lancet 2009; 373:1275-81.
Krum, et al., “Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension.” New England Journal of Med, Aug. 2009, 361; 9, 3 pages.
Luippold, Gerd et al., “Chronic Renal Denervation Prevents Glomerular Hyperfiltration in Diabetic Rats”, Nephrol Dial Transplant, vol. 19, No. 2, 2004, pp. 342-347.
Mahfoud et al. “Treatment strategies for resistant arterial hypertension” Dtsch Arztebl Int. 2011;108:725-731.
Osborn, et al., “Effect of Renal Nerve Stimulation on Renal Blood Flow Autoregulation and Antinatriuresis During Reductions in Renal Perfusion Pressure,” Proceedings of the Society for Experimental Biology and Medicine, vol. 168, 77-81, 1981.
Page, I.H. et al., “The Effect of Renal Denervation on Patients Suffering From Nephritis,” Feb. 27, 1935;443-458.
Page, I.H. et al., “The Effect of Renal Denervation on the Level of Arterial Blood Pressure and Renal Function in Essential Hypertension,” J. Clin Invest. 1934;14:27-30.
Rocha-Singh, “Catheter-Based Sympathetic Renal Denervation,” Endovascular Today, Aug. 2009, 4 pages.
Schlaich, M.P. et al., “Renal Denervation as a Therapeutic Approach for Hypertension: Novel Implications for an Old Concept,” Hypertension, 2009; 54:1195-1201.
Schlaich, M.P. et al., “Renal Sympathetic-Nerve Ablation for Uncontrolled Hypertension,” N Engl J Med 2009; 361(9): 932-934.
Smithwick, R.H. et al., “Splanchnicectomy for Essential Hypertension,” Journal Am Med Assn, 1953; 152:1501-1504.
Symplicity HTN-1 Investigators; Krum H, Barman N, Schlaich M, et al. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension. 2011;57(5):911-917.
Symplicity HTN-2 Investigators, “Renal Sympathetic Denervation in Patients with Treatment-Resistant Hypertension (The Symplicity HTN-2 Trial): A Randomised Controlled Trial”; Lancet, Dec. 4, 2010, vol. 376, pp. 1903-1909.
United States Renal Data System, USRDS 2003 Annual Data Report: Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2003, 593 pages.
Valente, John F. et al., “Laparoscopic Renal Denervation for Intractable ADPKD-Related Pain”, Nephrol Dial Transplant (2001) 16: 1 page.
Wagner, C.D. et al., “Very Low Frequency Oscillations in Arterial Blood Pressure After Autonomic Blockade in Conscious Dogs,” Feb. 5, 1997, Am J Physiol Regul Integr Comp Physiol 1997, vol. 272, 1997 The American Physiological Society, pp. 2034-2039.
Medtronic, “Symplicity Spyral™ Multi-Electrode Renal Denervation Catheter,” Instructions for Use, Jul. 2016, Doc No. M967336A001, Rev. 1A, 144 pages.
International Search Report and Written Opinion for International Application No. PCT/US2015/013042; dated Apr. 7, 2015; 10 pages.
Related Publications (1)
Number Date Country
20190117302 A1 Apr 2019 US
Provisional Applications (1)
Number Date Country
61932224 Jan 2014 US
Continuations (1)
Number Date Country
Parent 14606821 Jan 2015 US
Child 16229147 US